Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Psoriasis causes as much disability as other major medical diseases

Stephen R. Rapp, Steven R. Feldman, M. Lyn Exum et al. · Journal of the American Academy of Dermatology · 1999 · 1.5K citations

Medicine, Clinical Sciences, Dermatology +12

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Roy Fleischmann, Joel M. Kremer, John J. Cush et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text

Medicine, Immunology, Pharmacology +13